Drug intelligence / Profile preview

PTT-A

Development stage: Preclinical
Lead developer: Pep2Tango Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

PTT-A is a synthetic peptide drug candidate developed by Pep2Tango Therapeutics. It acts as a tetra-agonist, modulating both the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide 1 receptor (GLP-1R). The drug is being investigated for its potential to treat obesity, with preclinical data suggesting it may offer superior weight loss efficacy compared to existing agents like tirzepatide, along with improvements in blood lipid profiles, glycemic control, and liver health. As of May 2025, PTT-A is in IND-enabling studies with an anticipated IND submission expected within the year[1].

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on PTT-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTT-A.

Explore the full profile